FTO and gastric cancer: The results of the Meta-analysis showed that higher expression levels of FTO were associated with TMN stage (OR = 1.83, 95% CI: 1.11–3.03, P = .019), liver metastases (OR = 3.73, 95% CI: 1.49–9.31, P = .005), vascular invasion (OR = 2.22, 95% CI: 1.36–3.61, P = .001), poorer overall survival (OS) (HR = 0.46, 95% CI: 0.34–0.58, P < .001) and recurrence-free survival (HR = 0.56, 95% CI: 0.40–0.73, P < .001) in gastric cancer patients.